EP0484403A1 - Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines - Google Patents

Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines

Info

Publication number
EP0484403A1
EP0484403A1 EP90911529A EP90911529A EP0484403A1 EP 0484403 A1 EP0484403 A1 EP 0484403A1 EP 90911529 A EP90911529 A EP 90911529A EP 90911529 A EP90911529 A EP 90911529A EP 0484403 A1 EP0484403 A1 EP 0484403A1
Authority
EP
European Patent Office
Prior art keywords
conjugate
analog
immunogenic carrier
lipid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90911529A
Other languages
German (de)
French (fr)
Other versions
EP0484403A4 (en
Inventor
Nelson Teng
Jerald Sadoff
Apurba Bhattacharjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Univax Biologics Inc
Original Assignee
Univax Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univax Biologics Inc filed Critical Univax Biologics Inc
Publication of EP0484403A1 publication Critical patent/EP0484403A1/en
Publication of EP0484403A4 publication Critical patent/EP0484403A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Definitions

  • This invention is in the field of pharmaceutical compositions and the use thereof as vaccines.
  • LPS lipopolysaccharide
  • anti-LPS anti- serura Such antiserum may also facilitate the removal of Gram-negative bacteria by the reticuloendothelial system.
  • Several workers have demonstrated successful broad-spectrum protection against challenge by several Gram-negative organisms or endotoxins in different animal models by using rough mutants of E. coli or S. minnesota as immunizing agents to generate antisera. Braude, A. I., et al., J. Immunol . 108:505-512 (1972); Braude, A.I., et al.. J. Infect. Pis.
  • Typical Gram-negative bacterial LPS has three major structural regions: the 0-polysaccharide, the R-core oligosaccharide, and lipid A.
  • the structure of the O-polysaccharide is highly variable between organisms, even In the same species. Its antigenicity serves as a basis, for serotyping the bacteria.
  • the R region is a bridge between the O-antigen and lipid A; its structure is similar in most Gram-negative bacteria.
  • Antibodies to LPS may promote phagocytosis or the death of the bacteria.
  • the O-antigen is the most antigenic component of the LPS, yet ft has little known toxicity.
  • Lipid A in contrast, contains the toxic center of the .molecule and is remarkably similar in structure across a wide range of bacterial genera. It is believed that the lipid A region of LPS is responsible for a complex array of inflammatory responses to tissue invasion by Gram-negative bacteria by directly stimulating host cells such as macro-phages, neutrophils, and endothelial cells which mediate the inflammatory changes. Responses are both toxic (hypotension, coagulation disturbances, death) and beneficial to the infected host (enhancement of antibody formation, mobilization of phagocytes, acute phase protein synthesis).
  • lipid A The structure of lipid A is depicted as Formula (I) below:
  • Lipid A is a glucosamine disaccharide that is phosphorylated at positions 1 and 4' and has six or seven esterified fatty acids.
  • Four molecules of 3-hydroxytetradecanoate are attached to the glucosamine disaccharide at positions 2, 3, 2', and 3'; the hydroxyl groups of the 3'-OH-14:0 residues at positions 2' and 3' (and sometimes 2) are substituted with normal fatty acids (dodecanoate, tetradecanoate, hexadecanoate) to form acyloxyacyl groups.
  • lipid A analogs and biosynthetic precursors of lipid A have been examined.
  • Luderitz, 0., et al.. Rev. Infect. Pis. 6:428-431 (1984) disclose the preparation of lipid A analogs and the relationship thereof between the chemical structure and biologic activity.
  • the authors report that phosphate substitution of the glucosamine disaccharide is not essential for the expression of antigenicity, and that the araine-bound 3-hydroxyacyl residues can be replaced by non-hydroxylated fatty acids without reduction of activity.
  • the immunodeterminant structure comprises the linkage region of the amide-linked fatty acids and glucosamine.
  • This altered bacterial LPS is therapeutically useful as a vaccine to prevent Gram-negative bacterial diseases by inducing antibodies to LPS, as an antidote to treat or prevent Gram-negative bacterial sepsis, or as an adjuvant to enhance formation of antibodies to other antigens.
  • the acyloxyacyl hydrolase itself may also be prophylactically or therapeutically useful to detoxify endogenous LPS in patients with Gram-negative bacterial diseases. This enzyme may also be used to remove toxic LPS from therapeutic injectants.
  • the invention relates to a lipid A analog/immunogenic carrier conjugate, wherein said lipid A analog the following Formula (III):
  • n 1 or 2;
  • R 1 and R 3 are the same or different and selected from the group consisting of hydrogen, a C 2 -C 18 acyl group, a 3-hydroxy C 3 -C 18 acyl groups, a 3-(C 2 -C 12 -acyloxy)-C 3 -C 18 acyl group and a linkage to an immunogenic carrier;
  • R 2 is selected from the group consisting of C 2 -C 18 acyl groups, 3-hydroxy C 3 -C 18 acyl groups, and 3-(C 2 -C 12 -acyloxy)-C 3 -C 18 acyl groups;
  • R 4 is hydrogen, a C 2 -C 18 acyl group, a phosphate group or a linkage to an immunogenic carrier
  • R 1 , R 3 or R 4 is a linkage to an immunogenic carrier, wherein said linkage does not interfere substantially with the ability of the lipid A analog to stimulate an immune response in an animal.
  • the invention relates to a lipid A analog/-immunogenic carrier conjugate having the following Formula (IV):
  • n, R 1 , R 2 , R 3 and R 4 are defined above;
  • A is an immunogenic carrier
  • n 0 or 1
  • p 1 to 200
  • L is a linker group which does not interfere substantially with the characteristic ability of the lipid A analog to stimulate an immune response in an animal
  • R 1 and R 3 are the same or different and selected from the group consisting of hydrogen, C 2 -C 18 acyl groups, 3-hydroxy C 3 -C 13 acyl groups, and 3-(C 2 -C 12 -acyloxy)-C 3 -C 18 acyl groups;
  • R 2 is selected from the group consisting of C 2 -C 18 acyl groups, 3-hydroxy C 3 -C 18 acyl groups, and 3-(C 2 -C 12 -acyloxy)-C 3 -C 18 acyl groups;
  • R 4 is hydrogen, a C 2 -C 18 acyl group or a phosphate group.
  • the invention also relates to a lipid A analog/immunogenic carrier conjugate having the following Formula (V):
  • n, m, p, L, R 1 , R 2 , R 3 and R 4 are defined above.
  • the invention also relates to a vaccine for the prophylaxis of septic shock comprising a lipid A analog/immunogenic carrier conjugate of the present invention together with a pharmaceutically acceptable carrier or adjuvant.
  • the invention also relates to a method for treating or preventing septic shock in an animal comprising administering a pharmaceutical composition to an animal comprising a lipid A analog/immunogenic carrier conjugate of the invention;
  • lipid A analog/immunogenic carrier conjugate is present in an amount effective to induce active immunity to LPS in an animal.
  • the invention also relates to intermediates useful for the preparation of the lipid A analog/immunogenic carrier conjugates of the invention.
  • the invention relates to lipid A analog/immunogenic carrier conjugates comprising glucose or a polyglucose molecule such as gentiobiose linked to an immunogenic carrier, wherein at least C 3 position of the glucose or gentiobiose moieties are substituted with an acyl group (R 2 ).
  • the immunogenic carrier may be linked to any free hydroxyl group on the Lipid A analog molecule, so long as the conjugate induces active immunity to LPS when administered to an animal.
  • the immunogenic carrier is linked to the C 1 or C 6 position of the glucose or polyglucose moiety.
  • lipid A analog/immunogenic carrier conjugates of the present invention include all non-amino saccharides and polysaccharides acylated at least at the C 3 position of at least one of the saccharide moieties and linked to an immunogenic carrier, wherein the conjugate induces active immunity to LPS when administered to an animal.
  • a lipid A analog/immunogenic carrier conjugate of the invention is considered to induce active immunity to LPS wherein when the conjugate is administered to an animal, anti-LPS antibodies are produced by the animal.
  • the efficacy of the anti-LPS antibodies can be tested, for example, by administering the sera of an immunized animal to a second animal followed by challenge of the second animal with LPS-producing bacteria (see Example 7, below). Where administration of the anti-LPS sera results in enhanced survival of the second animal, the conjugate is considered to induce immunity to LPS.
  • Anti-LPS antibodies can also be tested by inhibition of the Shwartzman reaction, a well-known biological response to LPS (Lee, L. et al.. In: Zweifach, B.W. et al. (eds.) THE INFLAMMATORY PROCESS. Academic Press, NY, 1965, p. 791). Animals, particularly rabbits, actively immunized with LPS or with one of the compositions of the present invention are given an appropriate LPS challenge to induce a localized Shwartzman reaction. Prevention or amelioration of the erythema, hemorrhage or necrotic reaction is evidence for the presence of anti-LPS antibodies.
  • serum from an animal immunized with LPS or with one of the compositions of the present invention is transferred to a naive rabbit, which is then tested for a Shwartzman reaction. Inhibition of the reaction is a measure of antibody activity.
  • the vaccines of the present invention are useful for the prophylaxis of septic shock in an animal which is due to the release of LPS endotoxin by Gram negative microorganisms.
  • Gram negative microorganisms include, but are not limited to Salmonella. Escherichia. Hemophilus and Neisseria. Klebsiella. Shiqella. Pseudomonas. Enterobacter, Acinetobacter, and Bacteroides. See Bergey's Manual of Systematic Microbiology.
  • the conjugates of the invention are useful as vaccines which induce active immunity toward LPS in animals.
  • animals are humans, however the invention is not intended to be so limiting. Any animal which may experience the beneficial effects of the vaccines of the invention are within the scope of animals which may be treated according to the claimed invention.
  • the invention relates to lipid A analog/immunogenic carrier conjugates having the Formula (IV):
  • A is an immunogenic carrier
  • L is a linker group which does not interfere substantially with the characteristic ability of the lipid A analog to stimulate an immune response in an animal
  • R 1 and R 3 are selected from the group consisting of hydrogen, C 2 -C 18 acyl groups, 3-hydroxy C 3 -C 18 acyl groups, and 3-(C 2 -C 12 -acyloxy)-C 3 -C 18 acyl groups;
  • n 0 or 1
  • n 1 or 2;
  • p 1 to 200
  • R 2 is selected from the group consisting of C 2 -C 18 acyl groups, 3-hydroxy C 3 -C 18 acyl groups, and 3-(C 2 -C 22 -acyloxy)-C 3 -C 18 acyl groups;
  • R 4 is hydrogen, a C 2 -C 18 acyl group or a phosphate group.
  • the invention also relates to a lipid A analog/immunogenic carrier conjugate having the following Formula (V):
  • n, m, p, L, R 1 , R 2 , R 3 and R 4 are defined above.
  • immunogenic carrier any macromolecule which is capable of inducing an immunogenic reaction in an animal. Since many small molecules such as the lipid A analogs of the invention do not induce active immunity by themselves, it is necessary to conjugate the analog to an immunogenic carrier to induce production of antibodies which are specific for the small molecule.
  • Such immunogenic carriers include, but are not limited to, proteins such as bovine serum albumin, diphtheria toxoid, tetanus toxoid, edestin, keyhole-limpet hemocyanin, Pseudomonal Toxin A, choleragenoid, cholera toxin, pertussis toxin, viral proteins, and eukaryotic proteins such as interferons, interleukins, or tumor necrosis factor.
  • proteins may be obtained from natural or recombinant sources according to methods known to those skilled in the art.
  • the immunogenic carrier may comprise a protein fragment comprising at least the immunogenic portion of the molecule.
  • immunogenic macromolecules which may be used in the practice of the invention include, but are not limited to, polysaccharides, tRNA, nonmetabolizable synthetic polymers such as polyvinylamine, polymethacrylic acid polyvinylpyrrolidone, mixed polycondensates (with relatively high molecular weight) of 4'4'-diaminodiphenylraethane-3,3'-dicarboxylic acid and 4-nitro-2-arainobenzoic acid (See Sela, M., Science 166:1365-1374 (1969)) or glycolipids, lipids or carbohydrates.
  • the immunogenic carrier is a protein.
  • linker group is intended one or more bifunctional molecules which can be used to link the immunogenic carrier to the lipid A analog and which do not interfere with the production of anti-lipid A antibodies in vivo.
  • the linker group may be attached to any part of the glucose or gentiobiose moiety so long as the point of attachment does not interfere with the production of anti-lipid A antibodies in vivo and thus interfere with the induction of active immunity.
  • Typical acyl groups which can be substituted on the carbohydrate moiety incl ude, but are not l imited to, acetate, propionate, butanoate, pentanoate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, palmitoyl , olelyl , myristoyl , stearoyl , 3-hydroxybutanoate, 3-hydroxypentanoate, 3-hydroxyhexanoate, 3-hydroxyheptanoate, 3-hydroxyoctanoate, 3-hydroxynonanoate, 3-hydroxydecanoate, 3-hydroxydecanoate, 3-hydroxypalmitoyl , 3-hydroxyoleyl , 3-hydroxymyristoyl , and 3-hydroxystearoyl groups.
  • R groups include the 3-(C 2 -C 12 acyloxy)-substituted aforementioned C 3 -C 18 acyl groups wherein the C 2 -C 12 acyloxy groups include, but are not l imited to, acetate, propanoate, butanoate, pentanoate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, and dodecanoate groups.
  • Preferred l ipid A analog/immunogenic carrier conjugates are derived from gentiobiose and have the following Formula (IX) :
  • a preferred l ipid A analog/immunogenic carrier conjugate is gentiobiose peracetate l inked at the exposition to an immunogenic carrier having the following Formula (X) :
  • lipid A analog/immunogenic carrier conjugate is an acyl glucose molecule l inked at the exposition having the Formul a (XI) :
  • Another prefeVred lipid A analog/immunogenic carrier conjugate is an acyl gentiobiose molecule linked at the C 6' -position to an immunogenic carrier having the Formula (XII):
  • Another preferred lipid A analog/immunogenic carrier conjugate is an acyl glucose molecule linked at the C 6' -position to an immunogenic carrier having the Formula (XIII):
  • the lipid A analog/immunogenic carrier conjugates linked at the exposition may be prepared (see Scheme I) by treatment of an appropriately substituted and protected carbohydrate with a reagent capable of linking the carbohydrate to the immunogenic carrier having Formula (XIV) either directly or through a linker group.
  • a reagent capable of linking the carbohydrate to the immunogenic carrier having Formula (XIV) either directly or through a linker group.
  • the acetobromo derivative (XVI) may then be reacted with a linker such as 2-aminoethanol (XVII), 3-aminopropanol, 4-aminobutanol, or 5-aminopentanol, to give the aminoethyl peracetate saccharide derivative (XVIII) which may be coupled to the immunogenic carrier (XIV) with, for example, 1-ethyl-3-(3-dimethyl-aminopro ⁇ yl) carbodiimide (EDAC) to give (IV).
  • EDAC 1-ethyl-3-(3-dimethyl-aminopro ⁇ yl) carbodiimide
  • the immunogenic peptide may be derivatized with a second bifunctional spacer group, such as succinic acid or any of the other linker groups having two carboxyl groups, to give the derivative (XIX).
  • a second bifunctional spacer group such as succinic acid or any of the other linker groups having two carboxyl groups
  • the derivative having Formula (XIX) may then be condensed with (XVIII) in the presence of EDAC to give (IV).
  • R 4 is a phosphate group
  • the hydroxy group may be phosphorylated prior to preparation of the conjugate by reacting an appropriately protected glucose or gentiobiose compound with the product of phosphorous acid and N-methylimidazole in the presence of HgCl 2 . This reaction allows the preparation of the phosphate ester at the free hydroxyl group.
  • the ratio of lipid A analog molecules per immunogenic carrier molecule may vary considerably according to the molecular weight of the immunogenic carrier, the number of binding sites on the immunogenic carrier capable of being coupled to the lipid A molecule, and the antigenic characteristics of the particular lipid A molecule.
  • the ratio of lipid A analog molecules to immunogenic carrier molecules may be about 1:1 to about 200:1.
  • the ratio may range from about 5:1 to about 100:1.
  • the immunogenic carrier is diphtheria toxoid
  • the ratio of lipid A analog molecules to diphtheria toxoid molecules may range from about 5:1 to about 40:1.
  • the conjugates may be prepared according to scheme II by the selective tritylation of, for example, the C 6' -position of gentiobiose (XX) with trityl chloride (XXI) to give the C 6' -trityl gentiobiose derivative (XXII).
  • XXI gentiobiose
  • XXII trityl chloride
  • XXIII acetic anhydride
  • the invention also relates to intermediates useful for the preparation of the lipid A analog/immunogenic carriers of the invention.
  • the invention relates to a 1-bromo-saccharide having the Formula (XXVI):
  • the invention also rel ates to the intermediate having Formul a (XXVII) :
  • the invention also relates to l ipid A analog/l inker conjugates having the Formula (XXVIII) :
  • the invention relates to a lipid A analog/linker conjugate having the Formula (XXIX):
  • the invention also relates to a lipid A analog/linker conjugate having the Formula (XXX):
  • the invention also relates to a lipid A analog/linker conjugate having the Formula (XXXI):
  • the invention also relates to a lipid A analog/linker conjugate having the Formula (XXXII):
  • the conjugates of the invention may be purified by any method known to those of ordinary skill in the art.
  • the conjugates may be purified by reverse phase chromatography, ion exchange chromatography, size exclusion chromatography, or by dialyzing the reaction product against water followed by freezedrying.
  • the conjugates may be purified by passing a solution of the conjugate through a column having anti-lipid A antibodies immobilized on a solid phase support. (See the Examples section of the application for a method of preparing antibodies to lipid A.)
  • Administration of the vaccine comprising the lipid A analog/immunogenic carrier conjugate of the present invention may be parenteral, intravenous, intramuscular, subcutaneous, intranasal, or any other suitable means. Preferably, administration is by subcutaneous or intramuscular means.
  • the dosage administered may be dependent upon the age, weight, kind of concurrent treatment, if any, and nature of the antigen administered.
  • the conjugate may be administered at a dosage of 0.001 to 25.0 ⁇ g/kg of animal weight.
  • the initial dose may be followed up with a booster dosage after a period of 4 weeks to enhance the immunogenic response. Further booster doses every six months may be administered for as long as the risk of infection and septic shock exists.
  • the lipid A analog/immunogenic carrier conjugates useful in the method of the present invention may be employed in such forms as capsules, liquid solutions, suspensions or elixirs for oral administration, or sterile liquid forms such as solutions or suspensions.
  • Any inert carrier is preferably used, such as saline, or phosphatebuffered saline, or any such carrier in which the compounds used in the method of the present invention have suitable solubility proper ties for use in the method of the present invention.
  • the vaccines may be in the form of single dose preparations or in multi-dose flasks which can be used for mass vaccination programs. Reference is made to Remington's Pharmaceutical Sciences.
  • the vaccines of the invention comprising the lipid A analog/-immunogenic carrier conjugates of the invention may further comprise adjuvants which enhance production of lipid A analog-specific antibodies.
  • adjuvants include, but are not limited to, various oil formulations such as Freund's complete adjuvant, the dipeptide known as MDP, saponin, aluminum hydroxide, Bordetella pertussis, dephosphorylated lipid A, or an interferon.
  • Freund's adjuvant is an emulsion of mineral oil and water which is mixed with the immunogenic substance. Although Freund's adjuvant is powerful, it is usually not administered to humans. Instead, the adjuvant alum (aluminum hydroxide) may be used for administration to a human. The conjugate may be absorbed onto the aluminum hydroxide from which it is slowly released after injection.
  • alum aluminum hydroxide
  • the lipid A analog/immunogenic peptide conjugate may also be encapsulated within liposomes according to Fullerton, U.S. Patent No. 4,235,877.
  • Gentiobiose octaacetate obtained from Sigma Chemical Co. (St. Louis, MO) was converted into the acetobromo derivative by dissolution in dichloromethane (1 gm in 5 ml ) and treatment with 33% HBr in glacial acetic acid (10 ml ) (Fluka) at 5oC for 45 minutes. A volume of dichloromethane equal to the total volume of the reaction mixture was added and the mixture transferred to a separatory funnel . The organic phase was washed with an equal volume of saturated sodium bicarbonate sol ution (3-4 times) , followed by two portions of water. The organic layer was then dried over MgSO 4 , filtered, and the solvent evaporated to give a syrup.
  • the acetobromogentiobiose was crystall ized from dichloromethane and diethyl ether, filtered and dried in a vacuum desiccator. The crystalline compound gave a single spot on T.L.C. and the H-1 NMR spectrum was correct.
  • Acetobromogentiobiose (5 gm in 5 ml chloroform) was coupled to 2-aminoethanol (0.5 ml , approx. 0.5 gm, in 1 ml chloroform) in the presence of drierite (1 gm; W.A. Hammond Drierite Co. ) . The mixture was stirred overnight at room temperature then filtered. The resulting aminoethyl gentiobiose heptaacetate (AGH) was first purified by chromatography on a column of sil ica gel (1.6X24 cm, 50 ml total volume) using an ethyl acetate-ethanol solvent mixture (19:1) as the eluting solvent.
  • BSA bovine serum albumin
  • Dioxane was the solvent found capable of dissolving both the protein carriers and the AGH ligand.
  • Suc-BSA (10 mg) was coupled to AGH in 20% 1,4-dioxane (2-3 ml; Fisher Scientific) in the presence of l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (10 mg; EDAC).
  • EDAC l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
  • the pH was monitored using pH paper and maintained at 5-6 by the addition of dilute HCl. Three additional portions of EDAC (10 mg) were added after 30 minute intervals.
  • the resulting conjugate (Suc-BSA-AGH) was dialyzed against water and then frozen. Analysis for reducing sugar by the phenol-sulfuric acid assay showed that the conjugate consisted of 27.4% AGH. This is about 35 moles of ligand/mole of protein.
  • DT Diphtheria Toxoid
  • AGH obtained according to Example 1
  • 1,4-dioxane was coupled to AGH in 25% 1,4-dioxane and 0.05M NaCl in the presence of EDAC.
  • the resulting conjugate (DT-AGH) was dialyzed against water and freeze-dried. Analysis demonstrated that 16% of the conjugate consisted of AGH.
  • 3-Aminopropanol was linked to acetobromogentiobiose (as described for 2-aminoethanol in Example 1).
  • Diphtheria toxoid (DT) was succinylated (as described for BSA in Example 1) to give Suc-DT which was then coupled to aminopropylgentiobiose heptaacetate (APGH; according to Example 2) to give Suc-DT-APGH.
  • gentiobiose octaacetate is insoluble in water, the protein conjugates dissolve easily.
  • These soluble conjugates were tested for their ability to bind anti-lipid A human monoclonal antibody (obtained by fusion of the heteromyeloma SHMA6(H4) with Epstein Barr virus (EBV) transformed lymphocytes from the spleen of a patient immunized with the J5 mutant of E. coli 0111-B4 which is deficient in the enzyme uridine 5'-diphosphategalactose 4-epimerase which prevents attachment of the side chains responsible for the marked antigenic diversity among Gram-negative bacteria) by enzymelinked solid phase immunoassay (ELISA).
  • EBV Epstein Barr virus
  • the gentiobiose octaacetate protein/diphtheria toxoid conjugate was administered to rabbits according to the immunization schedule outlined in Table 2.
  • Antibody titers were then determined by ELISA.
  • Sera from rabbits 1 and 2 was then assayed for antibodies specific for a series of antigens.
  • Table 3 shows that the rabbit sera has reactivity with LPS and diphtheria toxin, but little reactivity with APGH.
  • LPS 1 100 200 300 200 300
  • TT-APGH tetanus toxoid-APGH conjugate
  • Antibody specificity for LPS on boiled J5 was then determined by specific adsorption experiments.
  • the sera of rabbits was diluted 1:500 and adsorbed twice with boiled J5 organisms at 10% volume of ⁇ acked cells. The first adsorption was for 2 hours followed by a second overnight adsorption (both at 4oC). The J5 organisms were analyzed by GLC and found to be free of galactose.
  • the sera from the final bleeds of rabbits 1 and 5 were then assayed preand post-adsorption by ELISA using TT-APGH. The results are shown in Table 5.
  • Gentiobiose (4 gm, Sigma) was added slowly with stirring to pyridine (60 ml) and to the resulting suspension was added with stirring triphenylmethylchloride (4 gm, Aldrich). The mixture was stirred overnight at room temperature.
  • the solvent was evaporated off in a rotary evaporator and the resident pyridine was removed by co-distillation with toluene (3 ⁇ 15 ml).
  • the solid product was dissolved into dichloromethane (30 ml) and the solution was loaded onto a washed silica gel column (2.0 ⁇ 70 cm).
  • the excess trityl chloride was first eluted with ethyl acetate.
  • the 6'-O-trityl-gentiobiose was then eluted with methanol.
  • the fractions containing the product were combined and evaporated to dryness.
  • the vaccine was prepared for immunization studies by dissolving the lyophilized conjugate in sterile phosphate buffered saline to a final concentration of 200 ug/ml, followed by adsorption to aluminum oxide (Rhesorptar) overnight at 4oC.
  • the vaccine was administered intramuscularly to NZW rabbits at 50 ug per dose, and sera were collected periodically during the immunization schedule.
  • Vaccine was administered at weeks 0, 3, 6, 9, 12, and 16. Immunogenicity was determined by ELISA using a heterologous tetanus conjugate vaccine (1'-O-SucDT-GH) as the plate antigen at a concentration of 2 ug/ml.
  • Active and Passive Protection from a Localized Shwartzman Reaction A. Active Immunization: Three rabbits were immunized twice with Suc-DT-APGH (see Example 3) in aluminum hydroxide gel (20:1, w/w) and subsequently received 4 injections of the antigen in saline. To test development of a localized Shwartzman reaction, rabbits each received an intracutaneous injection of 50 ⁇ g E. coli 06 LPS followed 23 hours later with 25 ⁇ g LPS in 0.1 ml saline, intravenously.
  • Test rabbits were injected intracutaneously with 100 ⁇ g E. coli 06 LPS in 0.2ml saline. After 21 hours, rabbits received 15 ml of the hyperimmune serum or normal serum intravenously (in the ear vein) and 2 hours later were challenged by intravenous injection of 20 ⁇ g LPS in 0.2 ml. In the control rabbits receiving normal serum, 4 of 5 showed hemorrhage and 1 had tissue necrosis. Only 1 of 5 rabbits receiving hyperimmune serum showed a positive hemorrhagic reaction and none had any signs of necrosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne les conjugués porteurs et analogues/immunogènes de la lipide A, ainsi que leur utilisation comme vaccins pour la prophylaxie du choc septique chez les animaux.The invention relates to conjugates and analogs / immunogens of lipid A, as well as their use as vaccines for the prophylaxis of septic shock in animals.

Description

Title of the Invention
LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES AND THE USE THEREOF
AS VACCINES
Cross Reference to Related Application
This application is a continuation-in part of U.S. Application Serial No. 07/487,898 filed March 6, 1990, which is a continuation-in- part of U.S. Application Serial No. 07/385,860 filed July 27, 1989, the disclosures of which are fully incorporated by reference herein.
FIELD OF THE INVENTION:
This invention is in the field of pharmaceutical compositions and the use thereof as vaccines.
BACKGROUND OF THE INVENTION:
Each year approximately 194,000 patients in U.S. hospitals develop bacteremia; of these, about 75,000 die. Maki, D.G., in Nosocomial Infections. R.E. Dixon (ed.), pages 183-196, Yorke Medical Books, New York (1981). This high frequency of mortality occurs despite the aggressive use of potent antibiotics. The shortcomings of antibiotic therapy may be attributed to the relative impermeability of the outer membrane of Gram-negative bacteria to the drugs and to the inability of the drugs to counteract the lethal effects of bacterial endotoxin. Ziegler, E.J., et al.. N. Engl. J. Med. 307:1225-1230 (1982); Bogard, W.C.Jr et.al., Infect. Immun. 55:899-908 (1987).
One approach toward counteracting the lethal effects of lipopolysaccharide (LPS) endotoxin is the administration of anti-LPS anti- serura. Such antiserum may also facilitate the removal of Gram-negative bacteria by the reticuloendothelial system. Several workers have demonstrated successful broad-spectrum protection against challenge by several Gram-negative organisms or endotoxins in different animal models by using rough mutants of E. coli or S. minnesota as immunizing agents to generate antisera. Braude, A. I., et al., J. Immunol . 108:505-512 (1972); Braude, A.I., et al.. J. Infect. Pis. 136:S167-S173 (1977); Dunn, D.L., et al.. Surgery 92:212-219 (1982); McCabe, W.R., J. Immunol. 108:601-610 (1972); McCabe, W.R., et al.. J. Infect. Dis. 136:S161-S166 (1977); and Ziegler, E.J., et al., J. Immunol . 111:433-438 (1973). These mutants lack the O-specific polysaccharide and express on their surface portions of the LPS core which presumably contains antigenic determinants shared by most Gram-negative organisms. Passive immunization of patients with human antisera raised against the rough mutant E. coli J5 has been shown to be an efficacious supplement to antibiotics for the control of nosocomial infections. Ziegler, E.J., et al.. N. Enol. J. Med. 307:1225-1230 (1982).
It is now recognized that most of the biological activity of bacterial endotoxins reside in the lipid A moiety of the LPS molecule. Luderitz, 0., et al., Curr. Top. Membr. Transp. 17:79-151 (1982). Typical Gram-negative bacterial LPS has three major structural regions: the 0-polysaccharide, the R-core oligosaccharide, and lipid A. The structure of the O-polysaccharide is highly variable between organisms, even In the same species. Its antigenicity serves as a basis, for serotyping the bacteria. The R region is a bridge between the O-antigen and lipid A; its structure is similar in most Gram-negative bacteria. Antibodies to LPS may promote phagocytosis or the death of the bacteria. The O-antigen is the most antigenic component of the LPS, yet ft has little known toxicity. Lipid A, in contrast, contains the toxic center of the .molecule and is remarkably similar in structure across a wide range of bacterial genera. It is believed that the lipid A region of LPS is responsible for a complex array of inflammatory responses to tissue invasion by Gram-negative bacteria by directly stimulating host cells such as macro-phages, neutrophils, and endothelial cells which mediate the inflammatory changes. Responses are both toxic (hypotension, coagulation disturbances, death) and beneficial to the infected host (enhancement of antibody formation, mobilization of phagocytes, acute phase protein synthesis).
The structure of lipid A is depicted as Formula (I) below:
Lipid A is a glucosamine disaccharide that is phosphorylated at positions 1 and 4' and has six or seven esterified fatty acids. Four molecules of 3-hydroxytetradecanoate are attached to the glucosamine disaccharide at positions 2, 3, 2', and 3'; the hydroxyl groups of the 3'-OH-14:0 residues at positions 2' and 3' (and sometimes 2) are substituted with normal fatty acids (dodecanoate, tetradecanoate, hexadecanoate) to form acyloxyacyl groups.
In order to gain insight into the structure-activity relationship of lipid A, the biological activity of chemically synthesized lipid A analogs and biosynthetic precursors of lipid A has been examined. For example, Luderitz, 0., et al.. Rev. Infect. Pis. 6:428-431 (1984), disclose the preparation of lipid A analogs and the relationship thereof between the chemical structure and biologic activity. The authors report that phosphate substitution of the glucosamine disaccharide is not essential for the expression of antigenicity, and that the araine-bound 3-hydroxyacyl residues can be replaced by non-hydroxylated fatty acids without reduction of activity. The authors also indicate that the immunodeterminant structure comprises the linkage region of the amide-linked fatty acids and glucosamine.
Galanos, C, et al.. Rev. Infect. Pis. 6:546-552 (1984), disclose the preparation of seraisynthetic lipid A immunogens comprising glucosamine disaccharide carrying one amide-linked 3-hydroxymyristic acid conjugated to a protein (edestin) for immunization of rabbits. Antibodies were produced in titers comparable to those obtained by immunization under similar conditions with acid-treated bacteria coated with lipid A.
Behling, U.H., et al., J. Immunol. 117:847-851 (1976), disclose the preparation of synthetic glycolipid adjuvants comprising N-palmitoyl-D-glucosamine, N-oleyl-D-glucosaraine, N-myristoyl-D-glucosamine, N-decanoyI~D-glucosaraine, and N-stearoyl-D-glucosamine. The authors report that comparable or superior enhancement of the immune response was obtained with the synthetic glycolipids in comparison to the use of LPS endotoxin in assays measuring anti-sheep red blood cell (SRBC) or gamma-globulin (HGG) hemagglutinin titers. The authors also report that the synthetic glycolipids have no activity in chick embryo lethality, Shwartzman skin assay, and Limulus lysate tests which are characteristic as well as sensitive assays of endotoxicity. Therefore, the authors conclude that the mitogenic and adjuvant effects by otherwise nonendotoxic glycolipids suggest that not all biologic properties of the endotoxin are related to one structural subunit or to one structural feature of this very complex molecule.
Hodgins, D.S., PCT Application Publication No. WO87/07297, published December 3, 1987, discloses LPS derivatives of reduced toxicity obtained by treatment of lipid A with an acyloxyacyl hydrolase to give a compound of the Formula (II):
This altered bacterial LPS is therapeutically useful as a vaccine to prevent Gram-negative bacterial diseases by inducing antibodies to LPS, as an antidote to treat or prevent Gram-negative bacterial sepsis, or as an adjuvant to enhance formation of antibodies to other antigens. The acyloxyacyl hydrolase itself may also be prophylactically or therapeutically useful to detoxify endogenous LPS in patients with Gram-negative bacterial diseases. This enzyme may also be used to remove toxic LPS from therapeutic injectants.
Despite the development of lipid A analogs as immunogens for induction of active immunity to LPS, a need continues to exist for new compounds which can be used in the treatment or prevention of septic shock in animals.
SUMMARY OF THE INVENTION
The invention relates to a lipid A analog/immunogenic carrier conjugate, wherein said lipid A analog the following Formula (III):
wherein n is 1 or 2;
R1 and R3 are the same or different and selected from the group consisting of hydrogen, a C2-C18 acyl group, a 3-hydroxy C3-C18 acyl groups, a 3-(C2-C12-acyloxy)-C3-C18 acyl group and a linkage to an immunogenic carrier;
R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group, a phosphate group or a linkage to an immunogenic carrier;
with the proviso that one of R1, R3 or R4 is a linkage to an immunogenic carrier, wherein said linkage does not interfere substantially with the ability of the lipid A analog to stimulate an immune response in an animal.
In particular, the invention relates to a lipid A analog/-immunogenic carrier conjugate having the following Formula (IV):
wherein n, R1, R2, R3 and R4 are defined above;
A is an immunogenic carrier;
m is 0 or 1;
p is 1 to 200;
L is a linker group which does not interfere substantially with the characteristic ability of the lipid A analog to stimulate an immune response in an animal;
R1 and R3 are the same or different and selected from the group consisting of hydrogen, C2-C18 acyl groups, 3-hydroxy C3-C13 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups;
R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group or a phosphate group.
The invention also relates to a lipid A analog/immunogenic carrier conjugate having the following Formula (V):
wherein n, m, p, L, R1, R2, R3 and R4 are defined above.
The invention also relates to a vaccine for the prophylaxis of septic shock comprising a lipid A analog/immunogenic carrier conjugate of the present invention together with a pharmaceutically acceptable carrier or adjuvant.
The invention also relates to a method for treating or preventing septic shock in an animal comprising administering a pharmaceutical composition to an animal comprising a lipid A analog/immunogenic carrier conjugate of the invention; and
a pharmaceutically acceptable carrier;
wherein said lipid A analog/immunogenic carrier conjugate is present in an amount effective to induce active immunity to LPS in an animal.
The invention also relates to intermediates useful for the preparation of the lipid A analog/immunogenic carrier conjugates of the invention.
Unexpectedly, the inventors of the present application have discovered that acyl derivatives of glucose and gentiobiose, when linked to an immunogenic carrier, induce active immunity to LPS in animals. This discovery allows the ready preparation of inexpensive vaccines which may be used for prophylaxis of septic shock. PESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention relates to lipid A analog/immunogenic carrier conjugates comprising glucose or a polyglucose molecule such as gentiobiose linked to an immunogenic carrier, wherein at least C3 position of the glucose or gentiobiose moieties are substituted with an acyl group (R2). The immunogenic carrier may be linked to any free hydroxyl group on the Lipid A analog molecule, so long as the conjugate induces active immunity to LPS when administered to an animal. Preferably, the immunogenic carrier is linked to the C1 or C6 position of the glucose or polyglucose moiety.
Equivalents of the lipid A analog/immunogenic carrier conjugates of the present invention include all non-amino saccharides and polysaccharides acylated at least at the C3 position of at least one of the saccharide moieties and linked to an immunogenic carrier, wherein the conjugate induces active immunity to LPS when administered to an animal.
A lipid A analog/immunogenic carrier conjugate of the invention is considered to induce active immunity to LPS wherein when the conjugate is administered to an animal, anti-LPS antibodies are produced by the animal. The efficacy of the anti-LPS antibodies can be tested, for example, by administering the sera of an immunized animal to a second animal followed by challenge of the second animal with LPS-producing bacteria (see Example 7, below). Where administration of the anti-LPS sera results in enhanced survival of the second animal, the conjugate is considered to induce immunity to LPS.
Anti-LPS antibodies can also be tested by inhibition of the Shwartzman reaction, a well-known biological response to LPS (Lee, L. et al.. In: Zweifach, B.W. et al. (eds.) THE INFLAMMATORY PROCESS. Academic Press, NY, 1965, p. 791). Animals, particularly rabbits, actively immunized with LPS or with one of the compositions of the present invention are given an appropriate LPS challenge to induce a localized Shwartzman reaction. Prevention or amelioration of the erythema, hemorrhage or necrotic reaction is evidence for the presence of anti-LPS antibodies. Alternatively, serum from an animal immunized with LPS or with one of the compositions of the present invention is transferred to a naive rabbit, which is then tested for a Shwartzman reaction. Inhibition of the reaction is a measure of antibody activity.
The vaccines of the present invention are useful for the prophylaxis of septic shock in an animal which is due to the release of LPS endotoxin by Gram negative microorganisms. Such Gram negative microorganisms include, but are not limited to Salmonella. Escherichia. Hemophilus and Neisseria. Klebsiella. Shiqella. Pseudomonas. Enterobacter, Acinetobacter, and Bacteroides. See Bergey's Manual of Systematic Microbiology.
The conjugates of the invention are useful as vaccines which induce active immunity toward LPS in animals. Preferably, such animals are humans, however the invention is not intended to be so limiting. Any animal which may experience the beneficial effects of the vaccines of the invention are within the scope of animals which may be treated according to the claimed invention.
In particular, the invention relates to lipid A analog/immunogenic carrier conjugates having the Formula (IV):
wherein A is an immunogenic carrier; L is a linker group which does not interfere substantially with the characteristic ability of the lipid A analog to stimulate an immune response in an animal;
R1 and R3 are selected from the group consisting of hydrogen, C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups;
m is 0 or 1;
n is 1 or 2;
p is 1 to 200;
R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C22-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group or a phosphate group.
The invention also relates to a lipid A analog/immunogenic carrier conjugate having the following Formula (V):
wherein n, m, p, L, R1, R2, R3 and R4 are defined above.
By the term "immunogenic carrier" is intended any macromolecule which is capable of inducing an immunogenic reaction in an animal. Since many small molecules such as the lipid A analogs of the invention do not induce active immunity by themselves, it is necessary to conjugate the analog to an immunogenic carrier to induce production of antibodies which are specific for the small molecule. Such immunogenic carriers include, but are not limited to, proteins such as bovine serum albumin, diphtheria toxoid, tetanus toxoid, edestin, keyhole-limpet hemocyanin, Pseudomonal Toxin A, choleragenoid, cholera toxin, pertussis toxin, viral proteins, and eukaryotic proteins such as interferons, interleukins, or tumor necrosis factor. Such proteins may be obtained from natural or recombinant sources according to methods known to those skilled in the art. When obtained from recombinant sources, the immunogenic carrier may comprise a protein fragment comprising at least the immunogenic portion of the molecule. Other known immunogenic macromolecules which may be used in the practice of the invention include, but are not limited to, polysaccharides, tRNA, nonmetabolizable synthetic polymers such as polyvinylamine, polymethacrylic acid polyvinylpyrrolidone, mixed polycondensates (with relatively high molecular weight) of 4'4'-diaminodiphenylraethane-3,3'-dicarboxylic acid and 4-nitro-2-arainobenzoic acid (See Sela, M., Science 166:1365-1374 (1969)) or glycolipids, lipids or carbohydrates. Preferably, the immunogenic carrier is a protein.
By the term "linker group" is intended one or more bifunctional molecules which can be used to link the immunogenic carrier to the lipid A analog and which do not interfere with the production of anti-lipid A antibodies in vivo. The linker group may be attached to any part of the glucose or gentiobiose moiety so long as the point of attachment does not interfere with the production of anti-lipid A antibodies in vivo and thus interfere with the induction of active immunity.
Examples of linker groups which can be used to link the lipid A analog to the immunogenic carrier may comprise
Typical acyl groups which can be substituted on the carbohydrate moiety incl ude, but are not l imited to, acetate, propionate, butanoate, pentanoate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, palmitoyl , olelyl , myristoyl , stearoyl , 3-hydroxybutanoate, 3-hydroxypentanoate, 3-hydroxyhexanoate, 3-hydroxyheptanoate, 3-hydroxyoctanoate, 3-hydroxynonanoate, 3-hydroxydecanoate, 3-hydroxydecanoate, 3-hydroxypalmitoyl , 3-hydroxyoleyl , 3-hydroxymyristoyl , and 3-hydroxystearoyl groups. Also included within the scope of R groups include the 3-(C2-C12 acyloxy)-substituted aforementioned C3-C18 acyl groups wherein the C2-C12 acyloxy groups include, but are not l imited to, acetate, propanoate, butanoate, pentanoate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, and dodecanoate groups.
Preferred l ipid A analog/immunogenic carrier conjugates are derived from gentiobiose and have the following Formula (IX) :
A preferred l ipid A analog/immunogenic carrier conjugate is gentiobiose peracetate l inked at the exposition to an immunogenic carrier having the following Formula (X) :
.Another preferred lipid A analog/immunogenic carrier conjugate is an acyl glucose molecule l inked at the exposition having the Formul a (XI) :
Another prefeVred lipid A analog/immunogenic carrier conjugate is an acyl gentiobiose molecule linked at the C6'-position to an immunogenic carrier having the Formula (XII):
Another preferred lipid A analog/immunogenic carrier conjugate is an acyl glucose molecule linked at the C6'-position to an immunogenic carrier having the Formula (XIII):
The lipid A analog/immunogenic carrier conjugates linked at the exposition may be prepared (see Scheme I) by treatment of an appropriately substituted and protected carbohydrate with a reagent capable of linking the carbohydrate to the immunogenic carrier having Formula (XIV) either directly or through a linker group. For example, gentiobiose or glucose peracetate (Formula (XV), n = 1 or 2; R1, R2, R3 and R4 = Ac) may be treated with HBr in glacial acetic acid to give the acetobromosaccharide derivative (XVI). The acetobromo derivative (XVI) may then be reacted with a linker such as 2-aminoethanol (XVII), 3-aminopropanol, 4-aminobutanol, or 5-aminopentanol, to give the aminoethyl peracetate saccharide derivative (XVIII) which may be coupled to the immunogenic carrier (XIV) with, for example, 1-ethyl-3-(3-dimethyl-aminoproρyl) carbodiimide (EDAC) to give (IV). The use of EDAC to form conjugates between amino containing substances and proteins is disclosed in U,S. Patent No. 4,526,714 to Feijen et al.
Alternatively, the immunogenic peptide may be derivatized with a second bifunctional spacer group, such as succinic acid or any of the other linker groups having two carboxyl groups, to give the derivative (XIX). The derivative having Formula (XIX) may then be condensed with (XVIII) in the presence of EDAC to give (IV).
Where R4 is a phosphate group, the hydroxy group may be phosphorylated prior to preparation of the conjugate by reacting an appropriately protected glucose or gentiobiose compound with the product of phosphorous acid and N-methylimidazole in the presence of HgCl2. This reaction allows the preparation of the phosphate ester at the free hydroxyl group.
The ratio of lipid A analog molecules per immunogenic carrier molecule may vary considerably according to the molecular weight of the immunogenic carrier, the number of binding sites on the immunogenic carrier capable of being coupled to the lipid A molecule, and the antigenic characteristics of the particular lipid A molecule. In general, the ratio of lipid A analog molecules to immunogenic carrier molecules may be about 1:1 to about 200:1. Preferably, the ratio may range from about 5:1 to about 100:1. More preferably, where the immunogenic carrier is diphtheria toxoid, the ratio of lipid A analog molecules to diphtheria toxoid molecules may range from about 5:1 to about 40:1.
Where the immunogenic carrier is linked to the lipid A molecule at the exposition, the conjugates may be prepared according to scheme II by the selective tritylation of, for example, the C6'-position of gentiobiose (XX) with trityl chloride (XXI) to give the C6'-trityl gentiobiose derivative (XXII). Acylation of the remaining hydroxyl groups with, for example, acetic anhydride gives 6,-O-tritylgentiobiose heptaacetate (XXIII). Removal of the trityl group with, for example, HBr gives the C6'-hydroxygentiobiose heptaacetate derivative (XXIV) which may be linked to an immunogenic carrier such as the succinate derivative of diphtheria toxoid to give (XXV).
The invention also relates to intermediates useful for the preparation of the lipid A analog/immunogenic carriers of the invention. In particular, the invention relates to a 1-bromo-saccharide having the Formula (XXVI):
wherein n=2.
The invention also rel ates to the intermediate having Formul a (XXVII) :
The invention also relates to l ipid A analog/l inker conjugates having the Formula (XXVIII) :
In particular, the invention relates to a lipid A analog/linker conjugate having the Formula (XXIX):
The invention also relates to a lipid A analog/linker conjugate having the Formula (XXX):
The invention also relates to a lipid A analog/linker conjugate having the Formula (XXXI):
The invention also relates to a lipid A analog/linker conjugate having the Formula (XXXII):
The conjugates of the invention may be purified by any method known to those of ordinary skill in the art. For example, the conjugates may be purified by reverse phase chromatography, ion exchange chromatography, size exclusion chromatography, or by dialyzing the reaction product against water followed by freezedrying. Alternatively, the conjugates may be purified by passing a solution of the conjugate through a column having anti-lipid A antibodies immobilized on a solid phase support. (See the Examples section of the application for a method of preparing antibodies to lipid A.)
Administration of the vaccine comprising the lipid A analog/immunogenic carrier conjugate of the present invention may be parenteral, intravenous, intramuscular, subcutaneous, intranasal, or any other suitable means. Preferably, administration is by subcutaneous or intramuscular means. The dosage administered may be dependent upon the age, weight, kind of concurrent treatment, if any, and nature of the antigen administered. In general, the conjugate may be administered at a dosage of 0.001 to 25.0 μg/kg of animal weight. The initial dose may be followed up with a booster dosage after a period of 4 weeks to enhance the immunogenic response. Further booster doses every six months may be administered for as long as the risk of infection and septic shock exists.
The lipid A analog/immunogenic carrier conjugates useful in the method of the present invention may be employed in such forms as capsules, liquid solutions, suspensions or elixirs for oral administration, or sterile liquid forms such as solutions or suspensions. Any inert carrier is preferably used, such as saline, or phosphatebuffered saline, or any such carrier in which the compounds used in the method of the present invention have suitable solubility proper ties for use in the method of the present invention. The vaccines may be in the form of single dose preparations or in multi-dose flasks which can be used for mass vaccination programs. Reference is made to Remington's Pharmaceutical Sciences. Mack Publishing Co., Easton, PA, Osol (ed.) (1980); and New Trends and Developments in Vaccines. Voller et al. (eds.), University Park Press, Baltimore, MD (1978), for methods of preparing and using vaccines.
The vaccines of the invention comprising the lipid A analog/-immunogenic carrier conjugates of the invention may further comprise adjuvants which enhance production of lipid A analog-specific antibodies. Such adjuvants include, but are not limited to, various oil formulations such as Freund's complete adjuvant, the dipeptide known as MDP, saponin, aluminum hydroxide, Bordetella pertussis, dephosphorylated lipid A, or an interferon.
Freund's adjuvant is an emulsion of mineral oil and water which is mixed with the immunogenic substance. Although Freund's adjuvant is powerful, it is usually not administered to humans. Instead, the adjuvant alum (aluminum hydroxide) may be used for administration to a human. The conjugate may be absorbed onto the aluminum hydroxide from which it is slowly released after injection.
The lipid A analog/immunogenic peptide conjugate may also be encapsulated within liposomes according to Fullerton, U.S. Patent No. 4,235,877.
Having now generally described the invention, the same may be further understood by reference to the following examples, which are not intended to be limiting unless so expressly stated.
EXAMPLES Example 1 : Preparation of a Gentiobiose peracetate-BSA conjugate
Gentiobiose octaacetate, obtained from Sigma Chemical Co. (St. Louis, MO) , was converted into the acetobromo derivative by dissolution in dichloromethane (1 gm in 5 ml ) and treatment with 33% HBr in glacial acetic acid (10 ml ) (Fluka) at 5ºC for 45 minutes. A volume of dichloromethane equal to the total volume of the reaction mixture was added and the mixture transferred to a separatory funnel . The organic phase was washed with an equal volume of saturated sodium bicarbonate sol ution (3-4 times) , followed by two portions of water. The organic layer was then dried over MgSO4, filtered, and the solvent evaporated to give a syrup. The acetobromogentiobiose was crystall ized from dichloromethane and diethyl ether, filtered and dried in a vacuum desiccator. The crystalline compound gave a single spot on T.L.C. and the H-1 NMR spectrum was correct.
Acetobromogentiobiose (5 gm in 5 ml chloroform) was coupled to 2-aminoethanol (0.5 ml , approx. 0.5 gm, in 1 ml chloroform) in the presence of drierite (1 gm; W.A. Hammond Drierite Co. ) . The mixture was stirred overnight at room temperature then filtered. The resulting aminoethyl gentiobiose heptaacetate (AGH) was first purified by chromatography on a column of sil ica gel (1.6X24 cm, 50 ml total volume) using an ethyl acetate-ethanol solvent mixture (19:1) as the eluting solvent. The fractions were screened by TLC using ethyl acetate-ethanol (19: 1) to elute. The fractions containing the aminoethyl derivative were combined, the solvent evaporated in vacuo. and the product crystallized from hot ethanol at 55ºC. The crystal ¬l ine compound gave a single spot on T.L.C. and had a melting point of 176-177ºC. El emental analysis showed C, 49.44%; H, 6.05%; N, 2.1% (cal cul ated for C28H40O28 N: C, 49.56%; H, 5.94%; N, 2.06%) . In order to increase the number of free carboxyl groups and solubility of bovine serum albumin (BSA), the BSA (10-50 mg in PBS at 4-5 mg/ml) was slowly treated with succinic anhydride (5-10 mg/mg protein; Aldrich Gold Label) at pH 8-9. The pH was maintained at 8-8.5 by the addition of concentrated NaOH. The reaction mixture was then extensively dialyzed against water and the resulting succinylated BSA (Suc-BSA) freeze-dried.
Dioxane was the solvent found capable of dissolving both the protein carriers and the AGH ligand. Suc-BSA (10 mg) was coupled to AGH in 20% 1,4-dioxane (2-3 ml; Fisher Scientific) in the presence of l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (10 mg; EDAC). The pH was monitored using pH paper and maintained at 5-6 by the addition of dilute HCl. Three additional portions of EDAC (10 mg) were added after 30 minute intervals. The resulting conjugate (Suc-BSA-AGH) was dialyzed against water and then frozen. Analysis for reducing sugar by the phenol-sulfuric acid assay showed that the conjugate consisted of 27.4% AGH. This is about 35 moles of ligand/mole of protein.
Example 2: Preparation of a Gentiobiose Peracetate-DT Conjugate
Diphtheria Toxoid (DT) from SSVI (Bern, Switzerland) was coupled to AGH (obtained according to Example 1) in 25% 1,4-dioxane and 0.05M NaCl in the presence of EDAC. The resulting conjugate (DT-AGH) was dialyzed against water and freeze-dried. Analysis demonstrated that 16% of the conjugate consisted of AGH.
Example 3: Preparation of Aminopropylgentiobiose Heptaacetate- Succinyl-DT Conjugate
3-Aminopropanol was linked to acetobromogentiobiose (as described for 2-aminoethanol in Example 1). Diphtheria toxoid (DT) was succinylated (as described for BSA in Example 1) to give Suc-DT which was then coupled to aminopropylgentiobiose heptaacetate (APGH; according to Example 2) to give Suc-DT-APGH.
Example 4: Binding of Gentiobiose-Protein Carrier Conjugates to LPS specific antibodies
Although gentiobiose octaacetate is insoluble in water, the protein conjugates dissolve easily. These soluble conjugates were tested for their ability to bind anti-lipid A human monoclonal antibody (obtained by fusion of the heteromyeloma SHMA6(H4) with Epstein Barr virus (EBV) transformed lymphocytes from the spleen of a patient immunized with the J5 mutant of E. coli 0111-B4 which is deficient in the enzyme uridine 5'-diphosphategalactose 4-epimerase which prevents attachment of the side chains responsible for the marked antigenic diversity among Gram-negative bacteria) by enzymelinked solid phase immunoassay (ELISA). As shown in Table 1, both BSA-gentiobiose octaacetate and diphtheria toxoid-gentiobiose octaacetate conjugates were able to bind the human monoclonal antibody. These experiments demonstrate that the important binding epitope remained intact during the conjugation process. Therefore, it would be expected by one of ordinary skill in the art that anti-lipid A antibodies would be produced in vivo upon administration of the lipid A analog/immunogenic carrier conjugates to an animal. Table 1
Binding of the lipid A Antibody to
Gentiobiose Octaacetate/Protein Conjugate
Suc-BSA-AGH conjugate 2,560
Suc-BSA-Control 640
DT-AGH conjugate 48
DT control 0
AGH in ethanol 1,280
E. coli Lipid A 2,560
Suc-DT-APGH 3,200
Suc-DT (control) 0
Example 5 In Vivo Immunogenicitv of the Gentiobiose Octaacetate/
Protein Conjugate in Rabbits
The gentiobiose octaacetate protein/diphtheria toxoid conjugate was administered to rabbits according to the immunization schedule outlined in Table 2. Antibody titers were then determined by ELISA. Sera from rabbits 1 and 2 was then assayed for antibodies specific for a series of antigens. Table 3 shows that the rabbit sera has reactivity with LPS and diphtheria toxin, but little reactivity with APGH.
Table 2
Rabbit No. Vaccine Dose Adjuvant Date
1& 2 SUC-DT-APGH 200 ug Freund's 4/11/88
Lot AKB III-A 200 ug Freund's 4/20/88
Substitution: 5.2%a 200 ug None 4/29/88
150 ug None 5/25/88
150 ug None 6/30/88
150 ug None 8/15/88
150 ug None 10/28/88
150 ug None 1/4/89
Animals bled out 1/12/89
3 & 4 Suc-DT-APGH
Lot AKB III-A-171
Substitution: 20%a
5 & 6 Suc-DT-APGH
Lot AKB V-33A
Substitution: 4.4%a
All four animals immunized 100 ug Alum 11/2/88 on same schedule: 100 ug Alum 11/30/88
100 ug None 12/31/88
100 ug None 1/13/89
100 ug None 2/17/89 aSubstitution of succinylated diphtheria toxin by APGH expressed as weight percent.
Table 3
Post bleeds
Pre-bleed
Antigen Rabbit 4/11 4/29 5/13 6/17 7/11
J5 LPS
1 150a 300 400 800 800
2 200 200 300 600 1,000
Men Gr B
LPS 1 100 200 300 200 300
2 100 150 250 250 300
APGH 1 <100 <100 100 150 150
2 <100 100 100 150 250
DT 1 300 1,600 6,400 12 ,800 >12,800
2 300 12,800 12,800 >12 ,800 >12,800 aAll data is expressed as the dilution giving an optical density reading of 0.4 units.
Rabbit sera was also assayed against a tetanus toxoid-APGH conjugate (TT-APGH), which does not have a spacer group. The results listed in Table 4 show that the antibodies are also specific for this conjugate, confirming that the antibodies are reactive with the APGH part of the molecule.
Table 4
Post bleeds
Antigen Rabbit Pre-bleed 1/4/89 1/12/89 1/24/89
TT-APGH
(no spacer)
1 100a 12,800 2 100 >12,800
3 100 4,800 1,600 4 100 800 1,600 5 100 1,200 3,200 6 100 600 800 aAll data is expressed as the dilution giving an optical-density reading of 0.4 units.
Antibody specificity for LPS on boiled J5 was then determined by specific adsorption experiments. In each experiment, the sera of rabbits was diluted 1:500 and adsorbed twice with boiled J5 organisms at 10% volume of^acked cells. The first adsorption was for 2 hours followed by a second overnight adsorption (both at 4ºC). The J5 organisms were analyzed by GLC and found to be free of galactose. The sera from the final bleeds of rabbits 1 and 5 were then assayed preand post-adsorption by ELISA using TT-APGH. The results are shown in Table 5.
Table 5
Rabbit Number % Reduction
#5
Exp 1 39%
Exp 2 42%
#1 27% aPercent reduction at O.D. = 0.4. As shown in Table 5, there was significant reduction of antibody titer when the sera was adsorbed to J5 LPS. These data confirm the expectation that the sera of animals immunized with the conjugate is reactive with LPS on boiled J5.
Example 6 Preparation of 6'-Substituted Gentiobiose Heptaacetate
Succinyl-Diphtheria Toxoid (SUC-DT) Conjugate
A. Preparation of 6'-O-Trityl -Gentiobiose
Gentiobiose (4 gm, Sigma) was added slowly with stirring to pyridine (60 ml) and to the resulting suspension was added with stirring triphenylmethylchloride (4 gm, Aldrich). The mixture was stirred overnight at room temperature.
The solvent was evaporated off in a rotary evaporator and the resident pyridine was removed by co-distillation with toluene (3 × 15 ml). The solid product was dissolved into dichloromethane (30 ml) and the solution was loaded onto a washed silica gel column (2.0 × 70 cm). The excess trityl chloride was first eluted with ethyl acetate. The 6'-O-trityl-gentiobiose was then eluted with methanol. The fractions containing the product were combined and evaporated to dryness.
B. Preparation of 6'-0-Trityl-Gentiobiose Heptaacetate
6'-O-Trityl-gentiobiose was dissolved into pyridine (35 ml) and to this solution was added with stirring 17 ml of acetic anhydride (Aldrich Chemical Corporation, Milwaukee, WI). The mixture was stirred overnight at room temperature and then poured into 400 ml of crushed ice. The resulting precipitate was filtered, washed with cold water and dried under vacuum (yield 5.5 gms). C. Preparation of 6'-0-Hvdroχy-Gentiobiose Heptaacetate (C-6'- HGH)
1.0 gm of 6'-O-trityl-gentiobiose heptaacetate was dissolved into 5.0 ml of glacial acetic acid and to this solution was added 33% HBr in glacial acetic acid (Fluka) to make 2% HBr. The mixture was poured into 50 ml of iced water and the resulting precipitate (trityl bromide) was filtered out.
The aqueous solution was extracted with dichloromethane (50 ml) and the organic phase was washed with saturated NaHCO3 solution, cold water, dried with anhydrous sodium sulfate and evaporated to dryness. The solid product was crystallized from diethyl ether. Yield 150 mg.
D. Preparation of 6'-Hydroxy-Gentiobiose Heptaacetate Succinyl- Diphtheria Toxoid (SUC-DT) Conjugate.
Succinyl-DT (7.2 mg) was coupled to 6'-hydroxy-gentiobiose heptaacetate (3.5 lag) in 20% 1,4-dioxane (Fisher Scientific Co.) in the presence of l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (18 mg, EDAC). The pH was maintained between 5.7 and 6.0 with 0.1N HCl. Two additional portions of EDAC (10 mg) were added at 30 minute intervals. The resulting conjugate (6'-O-SucDT-GH) was dialyzed against water and then freeze dried. Analysis for reducing sugar by the phenol -sulfuric acid assay showed that the conjugate consisted of 20% 6'-HGH. This is about 30 moles of ligand/mole of protein.
Example 7 Immunogenicitv Studies of 6'-O-SucDT-GH Vaccine
The vaccine was prepared for immunization studies by dissolving the lyophilized conjugate in sterile phosphate buffered saline to a final concentration of 200 ug/ml, followed by adsorption to aluminum oxide (Rhesorptar) overnight at 4ºC. The vaccine was administered intramuscularly to NZW rabbits at 50 ug per dose, and sera were collected periodically during the immunization schedule. Vaccine was administered at weeks 0, 3, 6, 9, 12, and 16. Immunogenicity was determined by ELISA using a heterologous tetanus conjugate vaccine (1'-O-SucDT-GH) as the plate antigen at a concentration of 2 ug/ml. Sera were run in triplicate beginning at a 1/50 dilution, and data reduced to optical density (O.D.) units, the titer at which the O.D. is equal to 1.0. The results for serial bleeds obtained 1 week after each dose shown in Table 6.
Table 6
Immunogenicity of 6'-O-Suc-DT-GH Vaccine
Rabbit #
Wk 0 Wk 1 Wk 4 Wk 7 Wk 10 Wk 13 Wk 17
R008 22 111 2,208 1,844 2,947 3,661 1,206
R009 20 27 443 1,053 2,423 13,097 6,884
R010 23 82 215 926 3,890 3,925 2,775
R012 15 55 474 663 2,597 2,897 2,080
R014 13 43 2,374 1,232 1,232 1,312 590
The results show that the vaccine induced ligand-specific antibodies in each rabbit immunized. To determine the protective efficacy of these antibodies, their ability to protect mice in a hog mucin challenge model was assayed. Pooled sera obtained at week 14 from immunized rabbits, or pooled sera obtained from control rabbits not receiving the vaccine, were sterile filtered and administered intraperitoneally to NSA mice at a dose of 1.0 ml per mouse. Two hours later the mice were challenged with from 4.8 × 103 to 4.8 × 105 aeruginosa suspended in a 14% preparation of hog mucin. Mice were examined hourly for the next 72 hours and the time of death recorded. Table 7 reports the results of these studies. Table 7
Hog Mucin Challenge Model
Protection from Challenge with Pseudomonas aeruginosa
Group Challenge 72 hr P* Hours p**
(n-10) (cfu) survival surviving
(%) (Mean ± S.E.M.)
Immune 4.8×103 70 .0049 60.6±6.41 .0001 Normal 4.8×103 0 18.4±0.30
Immune 4.8×104 40 .01 47.6±7.01 .0022 Normal 4.8×104 0 18.0±0
Immune 4.8×105 30 .01 37.8±7.53 .0001 Normal 4.8×105 0 18.0±0
* X2 analysis of immune group vs all controls receiving < that challenge dose.
** Student's t test, one tailed
These data demonstrate that the vaccine was immunogenic and produced antibodies that protect mice against challenge with a virulent gram negative bacteria.
Example 8
Active and Passive Protection from a Localized Shwartzman Reaction A. Active Immunization: Three rabbits were immunized twice with Suc-DT-APGH (see Example 3) in aluminum hydroxide gel (20:1, w/w) and subsequently received 4 injections of the antigen in saline. To test development of a localized Shwartzman reaction, rabbits each received an intracutaneous injection of 50 μg E. coli 06 LPS followed 23 hours later with 25 μg LPS in 0.1 ml saline, intravenously. Only 1 of 3 immunized rabbits showed a positive erythema, although no hemorrhagic reaction, whereas 3 of 3 non-immune rabbits were positive for erythema and 2 had hemorrhagic reactions. No necrosis was observed. B. Passive Immunization: Rabbits whose sera were to be tested were immunized once with Suc-DT-APGH (Example 3) in complete Freund's adjuvant, followed by 7 injections of the antigen in saline. Serum obtained from these hyperimmunized rabbits had an antibody titer of 1:6400 measured in an ELISA with TT-APTGH.
Test rabbits were injected intracutaneously with 100 μg E. coli 06 LPS in 0.2ml saline. After 21 hours, rabbits received 15 ml of the hyperimmune serum or normal serum intravenously (in the ear vein) and 2 hours later were challenged by intravenous injection of 20 μg LPS in 0.2 ml. In the control rabbits receiving normal serum, 4 of 5 showed hemorrhage and 1 had tissue necrosis. Only 1 of 5 rabbits receiving hyperimmune serum showed a positive hemorrhagic reaction and none had any signs of necrosis.
Therefore both active and passive immunization against Suc-DT-APGH afforded significant protection against the LPS-induced Shwartzman reaction, further confirming the capacity of the composition to induce anti-LPS antibodies capable of acting in vivo.
Having now fully described this invention, it will be understood by those of skill in the art that the same can be performed with any wide equivalent range of compositions, concentrations, formulation and other parameters without affecting the scope of the invention or any embodiment.

Claims

WHAT IS CLAIMED IS:
1. A l ipid A analog/immunogenic carrier conjugate comprising a l ipid A analog of the formula
wherein R1 and R3 are the same or different and selected from the group consisting of hydrogen, C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, a 3-(C2-C12-acyloxy)-C3-C18 acyl group or a linkage to an immunogenic carrier;
R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group, a phosphate group or a linkage to an immunogenic carrier; n = 1 or 2;
with the proviso that one of R1, R3 or R4 is a linkage to an immunogenic carrier, wherein said linkage does not interfere substantially with the ability of the lipid A analog to stimulate an immune response in an animal.
2. A lipid A analog/immunogenic carrier conjugate having the following formula:
wherein A is an immunogenic carrier;
m is 0 or 1;
n is 1 or 2;
p is 1 to 200;
L is a linker group which does not interfere substantially with the characteristic ability of the lipid A analog to stimulate an immune response in an animal;
R1 and R3 are the same or different and selected from the group consisting of hydrogen, C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups;
R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group or a phosphate group;
wherein said conjugate induces active immunity to LPS when administered to an animal.
3. The lipid A analog/immunogenic carrier conjugate of claim 2, wherein said linker group comprises -O-(CH2)q-NH-, wherein q is 2-3.
4. The lipid A analog/immunogenic carrier conjugate of claim 2, wherein L is
5. The lipid A analog/immunogenic carrier conjugate of claim 2, wherein L is wherein
1-3.
6. The lipid A analog/immunogenic carrier conjugate of claim 1, wherein said immunogenic carrier 1s a protein selected from the group consisting of bovine, serum albumin, diphtheria toxoid, edestin, Toxin A and choleragenoid.
7. A lipid A analog/immunogenic carrier conjugate having the formula:
wherein A is an immunogenic carrier;
m is 0 or 1;
p is 1 to 200;
L is a l inker group which does not Interfere substantially with the characteristic ability of the l ipid A analog to stimulate an immune response in an animal ;
R1 and R3 are selected from the group consisting of hydrogen, C2-C18 acyl groijps, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups; R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group or a phosphate group;
wherein said conjugate induces active immunity to LPS when administered to an animal.
8. The conjugate of claim 7, wherein the immunogenic carrier is a protein selected from the group consisting of bovine serum albumin, diphtheria toxoid, edestin, Toxin A and choleragenoid.
9. The lipid A analog/immunogenic carrier conjugate of claim 7, wherein said linker group comprises -O-(CH2)q-NH-, wherein q is 2-5.
10. The lipid A analog/immunogenic carrier conjugate of claim 7, wherein said linker group comprises
11. The lipid A analog/immunogenic carrier conjugate of claim 7, wherein L is
y = 1-3.
12. A l ipid A analog/immunogenic carrier conjugate having the formula:
wherein p is 1-200.
13. A lipid A analog/immunogenic carrier conjugate having the formula:
wherein p is 1 to 200.
14. A l ipid A analog/immunogenic carrier conjugate having the following formula:
wherein A is an immunogenic carrier;
m is 0 or 1;
n is 1 or 2;
p is 1 to 200;
L is a linker group which does not interfere substantially with the characteristic ability of the lipid A analog to stimulate an immune response in an animal;
R1 and R3 are the same or different and selected from the group consisting of hydrogen, C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C22-acyloxy)-C3-C18 acyl groups;
R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C22-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group or a phosphate group;
wherein said conjugate induces active immunity to LPS when administered to an animal.
15. The lipid A analog/immunogenic carrier conjugate of claim 14, wherein L is
16. The l ipid A analog/immunogenic carrier conjugate of cl aim 14, wherein said immunogenic carrier is a protein selected from the group consisting of bovine serum albumin, diphtheria toxoid, edestin, Toxin A and choleragenoid.
17. A lipid A analog/immunogenic carrier conjugate having the formula:
wherein A is an immunogenic carrier;
m is 0 of 1;
p is 1 to 200;
L is a linker group which does riot interfere substantially with the characteristic ability of the lipid A analog to stimulate an immune response in an animal;
R1 and R3 are selected from the group consisting of hydrogen, C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups;
R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group or a phosphate group;
wherein said conjugate induces active immunity to LPS when administered to an animal.
18. The conjugate of claim 17, wherein the immunogenic carrier is a protein selected from the group consisting of bovine serum albumin, diphtheria toxoid, edestin, Toxin A and choleragenoid.
19. The lipid A analog/immunogenic carrier conjugate of claim 17, wherein said linker group comprises
20. A lipid A analog/immunogenic carrier conjugate having the formula:
wherein p is 1-200.
21. A lipid A analog/immunogenic carrier conjugate having the formula:
wherein p is 1 to 200.
22. A vaccine for the prophylaxis of septic shock in an animal comprising:
(a) the lipid A analog/immunogenic carrier conjugate of claim 1; and
(b) a pharmaceutically acceptable carrier;
wherein said conjugate is present in an amount effective to induce active immunity to LPS in an animal.
23. The vaccine of claim 22, further comprising an adjuvant.
24. The vaccine of claim 22, wherein said conjugate has the formula:
wherein p is 1 to 200.
25. The vaccine of claim 22, wherein said conjugate has the formula:
wherein p is 1 to 200.
26. The vaccine of claim 22, wherein said conjugate has the formula:
wherein p is 1 to 200.
27. The vaccine of claim 22, wherein said conjugate has the formula:
wherein p is 1 to 200.
28. A method for treating or preventing septic shock in an animal comprising administering a pharmaceutical composition to an animal comprising:
(a) the lipid A analog/immunogenic carrier conjugate of claim 1; and (b) a pharmaceutically acceptable carrier;
wherein said lipid A analog/immunogenic carrier conjugate is present in an amount effective to induce active immunity to LPS in an animal.
29. The method of claim 28, wherein said amount effective is 0.001 to 25.0 μg/kg body weight of said animal.
30. The method of claim 28, wherein said conjugate has the formula:
wherein p is 1 to 200.
31. The method of claim 28, wherein said conjugate has the formula:
wherein p is 1 to 200.
32. The method of claim 28, wherein said conjugate has the formula:
wherein p is 1 to 200.
33. The method of cl aim 28, wherein said conjugate has the formula:
wherein p is 1 to 200.
34. A compound having the formula:
wherein n=2,
R1 and R3 are the same or different and selected from the group consisting of hydrogen, C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups;
R2 is selected from the group consisting of C2-C18 acyl groups, 3-hydroxy C3-C18 acyl groups, and 3-(C2-C12-acyloxy)-C3-C18 acyl groups; and
R4 is hydrogen, a C2-C18 acyl group or a phosphate group.
35. A compound having the formula:
36. A compound having the formula:
37. A compound having the formula:
38. A method of prepaparing a hyperimmune serum comprising administering the lipid A analog/immunogenic carrier conjugate of claim 1 to an animal and collecting the hyperimmunized serum.
EP19900911529 1989-07-27 1990-07-20 Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines Withdrawn EP0484403A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US38586089A 1989-07-27 1989-07-27
US385860 1989-07-27
US48789890A 1990-03-06 1990-03-06
US487898 1990-03-06
US50255590A 1990-04-02 1990-04-02
US502555 1990-04-02

Publications (2)

Publication Number Publication Date
EP0484403A1 true EP0484403A1 (en) 1992-05-13
EP0484403A4 EP0484403A4 (en) 1993-03-17

Family

ID=27409738

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900911529 Withdrawn EP0484403A4 (en) 1989-07-27 1990-07-20 Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines

Country Status (5)

Country Link
EP (1) EP0484403A4 (en)
JP (1) JPH04507244A (en)
AU (1) AU651319B2 (en)
CA (1) CA2064194A1 (en)
WO (1) WO1991001750A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5824310A (en) * 1991-10-22 1998-10-20 The United States Of America As Represented By The Department Of Health And Human Services Lipopplysaccharide conjugate vaccines
ES2104984T3 (en) * 1992-05-07 1997-10-16 American Cyanamid Co GLIPOCONJUGATED ANTIGENS WITH LIPID TO SYNTHETICS FOR USE IN VACCINES.
CA2330916C (en) 1998-05-19 2011-04-05 Research Development Foundation Triterpene compositions and methods for use thereof
EP1377320B1 (en) 2001-04-04 2008-10-01 Nordic Vaccine Technology A/S Polynucleotide binding complexes comprising sterols and saponins
WO2004058788A1 (en) * 2002-12-24 2004-07-15 Sankyo Company, Limited Lipid a analogues having glucose as the right sugar
CN108517014A (en) * 2012-08-21 2018-09-11 詹森药业有限公司 The antibody and application thereof of Risperidone haptens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63307897A (en) * 1987-06-09 1988-12-15 Toho Yakuhin Kogyo Kk Amphiphatic compound produced by bonding lipid a monosaccharide analog with sulfur-containing peptide glycan analog

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224788A1 (en) * 1981-07-17 1983-02-03 South African Inventions Development Corp., Scientia, Pretoria,Transvaal CARRIER-TIED IMMUNOGENIC MATERIAL
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63307897A (en) * 1987-06-09 1988-12-15 Toho Yakuhin Kogyo Kk Amphiphatic compound produced by bonding lipid a monosaccharide analog with sulfur-containing peptide glycan analog

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 104, 1986, Columbus, Ohio, US; abstract no. 110075, GORBACH et al.: 'Synthesis of lipid A analogs.Preparation of conjugate of 2-deox y-2-(3-hydroxytetradecanoyl)amino-D-glucos e 6-phosphate with polymeric carriers and their immunological properties' page 771, column 1, & BIOORG.KHIM. vol. 11, no. 5, 1985, pages 677 - 682 *
CHEMICAL ABSTRACTS, vol. 107, 1987, Columbus, Ohio, US; abstract no. 134579, GOUX ET AL 'Assignment of carbonyl resonances in carbon-13 NMR spectra of peracetylated mono-and oligosaccharides containing D-glucose and D-mannose:an alternative method for structural determination of complex carbohydrates' page 751, column 2, & CARBOHYDR.RES. vol. 159, no. 2, 1987, pages 191 - 210 *
CHEMICAL ABSTRACTS, vol. 111, 1989, Columbus, Ohio, US; abstract no. 78546, HASEGAWA ET AL 'Preparation of lipid a nonreducing monosaccharide analogs linked to peptidoglycan thio analogs having physiological activity' page 802, column 1, & JP - A - 63 307897 (TOHO PHARMACEUTICAL INDUSTRIES CO., LTD) 15 December 1988 *
CHEMICAL ABSTRACTS, vol. 87, 1977, Columbus, Ohio, US; abstract no. 147477, KING et al.: 'The preparation of carbohydrate-protein conjugates:cyanuric trichloride coupling of 2-aminoethyl glycosides,and mixed-anhydride coupling of 8-carboxyoctyl glycosides to bovine serum albumin' page 192, column 1, & CARBOHYDR.RES. vol. 55, 197, pages 83 - 93 *
CHEMICAL ABSTRACTS, vol. 97, 1982, Columbus, Ohio, US; abstract no. 110308, BOCK ET AL 'A conformational study of gentiobiose octaacetate by nuclear magnetic resonance spectroscopy and hard-sphere calculations' page 644, column 1, & NOUV.J.CHIM. vol. 6, no. 6, 1982, pages 301 - 304 *
HELVETICA CHIMICA ACTA vol. 67, no. 44, 1984, BASEL,CH pages 378 - 385 RYCHENER ET AL 'Synthesis and 1H-NMR study of the four unbranched peracetyl-beta-d-gl ucopyranosyl-beta-gentiobioses' *
MICROBIOL.IMMUNOL. vol. 29, no. 11, 1985, TOKYO,JP pages 1111 - 1120 SAITO-TAKI 'Comparison of murine b cell clonal expansions by synthetic lipid a and muramyl dipeptide analogs' *
See also references of WO9101750A1 *
VACCINE vol. 7, June 1989, GUILDFORD,UK pages 275 - 281, MAEDA et al.: 'adjuvant activities of synthetic lipid a subunit analogues and its conjugates with muramyl dipeptide derivatives' *

Also Published As

Publication number Publication date
CA2064194A1 (en) 1991-01-28
JPH04507244A (en) 1992-12-17
EP0484403A4 (en) 1993-03-17
AU6079590A (en) 1991-03-11
AU651319B2 (en) 1994-07-21
WO1991001750A1 (en) 1991-02-21

Similar Documents

Publication Publication Date Title
JP3717511B2 (en) Saponin-antigen complex and its use
JP2002504099A (en) Triterpene saponin analogs with adjuvant and immunostimulatory activity
AU651319B2 (en) Lipid A analog/immunogenic carrier conjugates and the use thereof as vaccines
WO2011133227A2 (en) Synthetic oligosaccharides for staphyloccocus vaccine
US11420993B2 (en) Semi-synthetic meningococcal conjugate vaccine
Andersen et al. Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome
US5637569A (en) Ganglioside analogs
JP6622804B2 (en) Vaccine against Streptococcus pneumoniae serotype 4
US20240024489A1 (en) Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof
EP1212334B1 (en) Oligosaccharides derived from ribose-ribitol-phosphate, and vaccines containing them
US20160375120A1 (en) Synthetic oligosaccharides for moraxella vaccine
EP0575517A1 (en) Lipid a analog/immunogenic carrier conjugates, the use thereof as vaccines and polyvalent hyperimmune gammaglobulins
US4767845A (en) Synthesis of tumor antigenic determinant
EP1000076A1 (en) HEXADECASACCHARIDE-PROTEIN CONJUGATE VACCINE FOR $i(SHIGELLA DYSENTERIAE) TYPE 1
JP3369555B2 (en) Receptor complexes that target drugs and other agents to their targets
JPS59175495A (en) Immunologically activating dipeptidyl d-glucose derivatives and manufacture
JPH0641200A (en) Synthetic lipid a sugar complex antigen
KR830002059B1 (en) Process for the preparation of novel compounds in the form of mul-amyl-pentide
CN118420796A (en) Synthesis method and application of campylobacter jejuni CG8486 capsular oligosaccharide and glycoprotein conjugate thereof
EP3000820A1 (en) Synthetic vaccines against Streptococcus pneumoniae serotype 8
MXPA99010675A (en) Triterpene saponin analogs having adjuvant and immunostimulatory activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930125

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950711